Uploaded February 2023 | Updated September 2026, 2 weeks ago
On Feb. 1, 2023, Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced the opening of the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.
Located in the International Renewable Energy Agency (IRENA) headquarters in Masdar City, Abu Dhabi’s flagship sustainable urban development, the research and development (R&D) hub will comprise global talent in AI and software development dedicated to expanding the capabilities of Insilico’s end-to-end AI-driven drug discovery platform, Pharma.AI, exploring aging research and sustainable chemistry, and supporting the digital transformation of healthcare in the region.
On Feb. 1, 2023, Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced the opening of the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.
Located in the International Renewable Energy Agency (IRENA) headquarters in Masdar City, Abu Dhabi’s flagship sustainable urban development, the research and development (R&D) hub will comprise global talent in AI and software development dedicated to expanding the capabilities of Insilico’s end-to-end AI-driven drug discovery platform, Pharma.AI, exploring aging research and sustainable chemistry, and supporting the digital transformation of healthcare in the region.
![[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors](https://i.ytimg.com/vi/R9wa1NeqVZg/mqdefault.jpg "[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors
Cold tumors are cancers with little to no immune cell infiltration. They lack the ability to activate the immune system, leaving patients with few options. Recently, Insilico Medicine announced breakthrough findings in immune oncology therapy targeting ENPP1, published in Nature Communications, a leading peer reviewed journal.")
